Safusidenib

N/A

Report date: 2026/03/24 20:00:35
NME

Base Information

Drug NameSafusidenib
Drug Alias NameSafusidenib erbumineDS-1001bDS-1001AB-218
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitors
TargetsIsocitrate dehydrogenase [NADP] cytoplasmic
Therapy Area/IndicationsSolid tumoursBiliary Tract NeoplasmsOligodendroglioma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAnHeart Therapeutics Co LtdDaiichi Sankyo Co LtdNuvation Bio Inc
Inactive CompaniesShanghai STA Pharmaceutical Product Co Ltd
Active IndicationsBiliary Tract NeoplasmsOligodendrogliomaGlioblastoma +[5] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A